Scinai Immunotherapeutics Ltd. SCNI
Regular-session close
After hours · Nov 16, 4:00 PM ET
- YTD
- -94.32%
- 1 year
- -95.87%
- Market cap
- 1.06M
- Revenue (ttm)
- 284.00K
- EPS (ttm)
- 3.30
- Shares out
- 853.00K
- P/E ratio
- 0.12
- YTD return
- -94.32%
- 1-year return
- -95.87%
- Volume
- 27.21K
- Avg volume
- 2.16M
- Open
- 0.3898
- Previous close
- 0.40
- Day's range
- 0.3898 – 0.4269
- 52-week range
- 0.387 – 13.00
- Beta
- 2.46
5D -0.0416 (-9.42%)
Key statistics
- 50-day average
- 3.41
- 200-day average
- 3.91
- Enterprise value
- 10.13B
- Price / sales
- 10.06
- Free cash flow
- -3.79M
- Total cash
- 3.08M
- Total debt
- 20.82M
- Short % of float
- 0.88%
Fundamental scorecard
3 of 25 checks passed on SCNI’s reported financials
3of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 2 of 5
- Dividend No data
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 22, 2024 | Sep 1, 2024 | 0.00 | 8.40 | — | — |
| Aug 15, 2024 | Jun 1, 2024 | 0.00 | -3.57 | — | — |
| Jul 2, 2024 | Mar 1, 2024 | 0.00 | -4.00 | — | — |
| May 15, 2024 | Dec 1, 2023 | 0.00 | -240.00 | — | — |
| Oct 31, 2023 | Sep 1, 2023 | 0.00 | -6.60 | — | — |
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- scinai.com
News
Your note
Sign in to keep a note on SCNI — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rhumbline Advisers | 0.19% | 1,653 | 5.54K | Sep 29, 2024 |
| Morgan Stanley | 0.03% | 255 | 854 | Sep 29, 2024 |
| Aspire Private Capital, LLC | 0.00% | 32 | 107 | Sep 29, 2024 |
| Credit Agricole S.A. | 0.00% | 42 | 140 | Sep 29, 2024 |
| UBS Group AG | 0.00% | 30 | 100 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR Portfolio Developed World ex-US ETF | 0.00% | 2 | 6 | Sep 29, 2024 |
